Role of Plasma Rich Growth Factor in Repair Primary Cleft Palate

Launched by CAIRO UNIVERSITY · Mar 16, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether a treatment called plasma-rich growth factor (PRGF) can help speed up healing and reduce the chance of complications after surgery for children with a condition known as a cleft palate. A cleft palate is a birth defect that affects the roof of the mouth, and this trial aims to see if using PRGF during surgery can make a difference.

To participate in the study, children aged between 6 months and 18 months who are otherwise healthy and have a non-syndromic (not part of a syndrome) isolated cleft palate may be eligible. However, children with previous palate surgeries, certain blood disorders, or who have received cancer treatments will not be included. The trial is not yet recruiting participants, but once it starts, families can expect to learn more about how PRGF affects recovery after surgery and if it lowers the risk of developing issues like oronasal fistulas, which are abnormal openings between the mouth and nose.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • systemically healthy patients (American Society of Anesthesiologists -ASA I and II); not older than 6-18 months
• • Patients with primary non-syndromic isolated cleft palate
• • Apprehensive to be in the study.
• Exclusion Criteria:
• • Patients with recurrent palatal fistula
• • Existence of syndromic cleft palate
• • Blood diseases and platelet disorders (hematological disease)
• • Systematic disease radiotherapy or chemotherapy for malignancy